​ ​ ​ ​ Research Studies | Ebv+ptld
Aller au contenu Aller au menu

Research Studies

Studies recruiting for EBV+ PTLD*1,2

Study Name/ID

Phase

Study Details

Regis

ALLELE ATA129-EBV-302~

3

Multicentre, open-label study for the treatment of EBV+ PTLD following SOT or HCT after failure of rituximab or rituximab + chemotherapy

NCT03394365

EBVision ATA129-EBV-205

2

Multicohort study in patients with EBV‑driven diseases, newly diagnosed or relapsed/refractory 

NCT04554914 

EBVOLVE

PASS

Observational, post-authorisation safety study to describe safety and effectiveness of tabelecleucel in patients with EBV+ PTLD in a real-world setting in Europe

EUPAS1000000113

REPLY

4

Multicentre, two-arm study to evaluate the efficacy of early infusion of rituximab in preventing EBV primary infection and PTLD in adult EBV– kidney transplant recipients transplanted with an EBV+ donor

NCT04989491

OSU-22114 

2

A trial to assess tafasitamab and rituximab as front-line treatment for patients with PTLD

NCT05786040

17-C-0125

2

A study to assess nivolumab in patients who have EBV+ lymphoproliferative disorders or EBV+ non-Hodgkin lymphomas with no standard therapy

NCT03258567

EBV-TCL-01

1/2

Open-label study assessing the safety and efficacy of T lymphocytes for the treatment of EBV infection or EBV-related lymphoproliferative diseases in patients not responding to standard of care

NCT02580539

202308116

1/2

A study to test vedotin in combination with rituximab in patients with treatment-naïve CD20+ PTLD

NCT06040320

EVITA

Observational

Observational study to estimate the incidence and clinical consequences of EBV DNAemia in whole blood and plasma in renal transplant recipients

NCT04189835

*as of February, 2025
~ Closed to recruitment in the US; recruitment ongoing for non-US patients.

References

  1. Clinicaltrials.gov. Accessed 17 July 2024. https://clinicaltrials.gov./ 
  2. European Medicines Agency. RWD Catalogues. An observational, Post-Authorisation Safety Study (PASS) to describe the safety and effectiveness of tabelecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world setting in Europe: EBVOLVE study. Accessed 19 September 2024. https://catalogues.ema.europa.eu/node/4014/administrative-details. 

Abbreviations

  • EBV(+)    Epstein–Barr virus (positive)
  • HCT    haematopoietic cell transplantation
  • PASS    Post-authorisation safety study
  • PTLD    post-transplant lymphoproliferative disorder
  • R/R    relapsed/refractory
  • SOT    solid organ transplant